Modality
Vaccine
MOA
AHRant
Target
C5
Pathway
Fibrosis
ET
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
Mar 2021
Phase 2Current
NCT04684500
752 pts·ET
2021-03→TBD·Active
752 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04684500 | Phase 2 | ET | Active | 752 | VA |
Competitors (10)